GE HealthCare has unveiled Vscan Air SL, a handheld wireless ultrasound system for cardiac and vascular assessments at the point of care, aiding clinicians in expediting diagnoses and treatment choices.
The latest addition to the Vscan product line, Vscan Air SL features GE HealthCare’s proprietary SignalMax and XDclear technology that provide high levels of penetration, resolution, and sensitivity in imaging performance with a single crystal transducer technology.
With cardiovascular disease being the most prevalent disease worldwide, often presenting in emergency situations, prompt diagnosis and treatment can be vital. The wireless Vscan Air SL is designed to enable clinicians to efficiently collect and view crystal clear cardiac and vascular images at the point of care. By streamlining these workflows and avoiding overloading traditional radiology resources, clinicians can expedite care decisions to help patients receive treatment plans right away.
“Having ever more powerful handheld ultrasound is a game-changer for patient care,” says Guy Lloyd, MD, FRCP, consultant cardiologist at Barts Heart Center, University College London Hospitals and clinical director for cardiovascular diagnostics and investigations. “Whether on the ward or in general practice, being able to provide high-quality imaging at the point of care means rapid diagnosis and rapid treatment.”
With Vscan Air SL, clinicians have a pocket-sized, portable tool that allows for whole-body scanning and secure viewing of images. In addition, through Vscan Air + Digital Tools, clinicians have access to subscriptions that can connect them to a suite of solutions designed to improve workflow with secure collaboration, image, and device management features.
“Vscan Air SL enables clinicians to make quick cardiac assessments and adds to our broad portfolio of ultrasound technologies to help further inform clinical decision making at the point of care,” says Dietmar Seifriedsberger, global general manager, point of care and handheld ultrasound at GE HealthCare. “This newest innovation demonstrates our commitment to providing integrated solutions resulting in better standard of care delivery—and ultimately helping clinicians improve patient outcomes.”
Vscan Air SL is currently commercially available in key countries throughout Europe and Asia as well as Australia and New Zealand. In the United States, Vscan Air SL is U.S. Food and Drug Administration 510(k) cleared and will become commercially available this quarter.